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Introduction
Most cancer cells exhibit genomic instability, often with mutations in genes encoding p53 and Rb pathway members, or oncoproteins such as Kras and c-myc, that compromise the G1 checkpoint (1, 2) . These cells are therefore dependent on the G2 checkpoint for survival following DNA damage (3) . G2 checkpoint abrogation is a therapeutic strategy designed to prevent cell cycle arrest in response to DNA damage, resulting in impaired DNA repair and increased tumor cell death (4) . Because non-transformed cells retain both the G1 checkpoint and backup p53-dependent pathways at the G2 checkpoint, G2 checkpoint abrogation in combination with DNA damage is expected to selectively enhance the death of transformed cells (3) .
Delay of cell cycle progression after DNA damage is initiated by activation of the phosphatidylinositol-3-kinase-like protein kinases ATM (ataxia-telangectasia mutated) and ATR (ATM and Rad3-related) (5) . These kinases phosphorylate substrates mediating checkpoint control and repair, including the checkpoint kinase Chk1 (6, 7) . To establish the G2 checkpoint, Chk1 phosphorylates the CDC25C phosphatase at Ser 216 , resulting in its cytoplasmic sequestration (8) (9) (10) . Consequently, inhibitory phosphates are not removed from cyclindependent kinase 1, so cells accumulate at the G2 boundary, allowing time for DNA repair prior to mitotic entry. Of note, Ser 216 of CDC25C is also phosphorylated by other kinases, including MAPKAP-kinase 2 (MAPKAP-K2) and C-TAK1 (11, 12) . 5 infusion UCN-01, therapeutic dose levels of cisplatin were not achieved (24, 25) . Nonetheless, evidence of target modulation has prompted alternative administration schedules and combinations (26, 27) , as well as the development of novel agents.
CBP501 is a stable synthetic dodecapeptide obtained during G2 abrogation phenotype-based optimization of the Chk1/2-inhibiting peptides TAT-216 and TAT-216A (28) . CBP501 inhibits the activities of multiple kinases that phosphorylate the Ser 216 residue of CDC25C, including Chk1, MAPKAP-K2 and C-Tak1, with no apparent activity on kinases upstream within the cascade. CBP501-mediated inhibition of these Ser 216 kinases causes reduced phosphorylation of CDC25C, and reduces cisplatin-mediated G2 accumulation when applied in combination to cancer-derived cell lines, but not in non-transformed cells, including human umbilical vein endothelial cells, normal human diploid fibroblasts and activated normal T lymphocytes (28) . As a result, CBP501 enhanced the cytotoxicity of cisplatin and bleomycin, in HCT116 colon cancer and MIAPaCa2 pancreatic cancer cells. In several instances, combining CBP501 with DNA damaging agents does not increase the proportion of cells in M phase, likely because cells are dying shortly after checkpoint abrogation (28, 29) . These results were extended to xenograft models, with CBP501 augmenting tumor growth delay in combination with cisplatin or bleomycin, compared to either drug alone. This effect was observed without increased toxicity and also resulted in improved overall survival (28) . Of note, compared to cells treated with cisplatin alone, co-administration of CBP501 was found to increase the intracellular cisplatin concentration, which may also contribute to the antitumor effects of this combination (29) .
Based on the preclinical confirmation of mechanism and the efficacy demonstrated both in vitro and in vivo, we conducted two phase I dose-finding and pharmacokinetic studies with CBP501 in 
Patients and Methods

Patient selection
These studies were conducted in compliance with the principles of CFR, ICH GCP and the Declaration of Helsinki. Protocols were approved by institutional review boards. All patients were required to provide informed consent before undergoing study-specific procedures.
Inclusion criteria included: pathologically-confirmed, locally advanced or metastatic solid tumors, refractory to standard therapy or for which conventional therapy is not reliably effective; age ≥18 years; ECOG PS 0-2 (0-1 for the combination study); life expectancy >3 months; 
Treatment Plan
Single-agent CBP501 was administered by 1-hour intravenous infusions for 3 consecutive weeks (days 1, 8, 15) , repeated every 28 days (starting dose 0.9 mg/m²); in the combination study, CBP501 (IV, starting dose 3.6 mg/m²) was administered one hour before cisplatin (IV, starting dose 50 mg/m²) on day 1 of a 3-week cycle. A cohort of patients treated at the MTD in the combination study received a single dose of CBP501 alone on day -7, so that CBP501 pharmacokinetics could be compared in the absence and presence of cisplatin.
Initially diphenhydramine was used in the single-agent study as prophylaxis for a histaminerelease syndrome (HRS) observed with CBP501 in animals (30, 31) . With successive modifications, the final prophylactic treatment in both studies consisted of dexamethasone (8 mg oral the night before, and 8 mg IV immediately before CBP501 administration), diphenhydramine and ranitidine (both at 50 mg IV immediately before CBP501 infusion) and loratadine (10 mg oral the day before, the day of CBP501 administration, and the day after) at each infusion. In the event of anaphylactoid reactions, standard treatment was administered.
Prophylactic antiemetics were administered according to standard treatment center regimens.
A standard 3+3 dose escalation scheme was employed: in the absence of dose-limiting toxicity (DLT) the dose was escalated to the next dose level (DL); if DLT was reported in one patient, 3 additional patients were to be included at that DL; if no further patients experienced DLT, the dose was escalated. If ≥2 out of 3-6 patients experienced DLT, escalation would be halted. The MTD was defined as the DL below that in which DLT was observed during the first two cycles in at least 2 out of 3-6 assessable patients. In each study, 6-12 additional patients were to be treated at the MTD to achieve a total of at least 10 evaluable patients to verify the MTD. Based on preliminary activity during dose escalation, 14 additional patients with ovarian or endometrial cancer were treated at the MTD in the combination study under a protocol amendment.
During dose escalation, increments were determined according to the severity of treatmentrelated adverse events observed during the observation period in the previous DL. In the singleagent study, in the absence of toxicity, dose escalation was by 100% increments; with grade 1 toxicity, 50% increments were used; with grade 2-4 toxicity, 33% increments were used.
In the combination study, dose escalation was conducted in two steps: first, cisplatin was evaluated at two dose levels (50 and 75 mg/m²) with a fixed dose of CBP501 (3.6 mg/m²); secondly, CBP501 was escalated, combined with the highest tolerated dose of cisplatin (75 mg/m²). CBP501 dose increments were as follows: with grade 0-1 toxicity, 100% increments; with grade 2-4 events (non-DLT), 50% increments; in case of DLTs, 33% increments were used.
DLT in both studies was defined as any of the following: grade 4 neutropenia lasting ≥ 7 days (≥ 5 days for the combination study) or grade 3-4 neutropenia with fever and/or infection; grade 4 thrombocytopenia (or grade 3 with bleeding); grade 3 or 4 treatment-related non-hematological toxicity (excluding grade 3 vomiting with sub-optimal treatment); dosing delay greater than 2 weeks following treatment-related adverse events or laboratory abnormalities.
Cardiac monitoring
Cardiac monitoring was conducted in both studies to address mild myocardial fibrosis associated with histamine release observed in preclinical toxicology studies (31) cycles), assessment of cardiac enzymes (CPK-MB, CPK-MM and troponin I, at baseline and prior to each administration), and electrocardiogram (ECG) assessment (before CBP501 infusion, at the end of infusion, and 1 hr after the end of infusion). In both studies, an interim central review of ECGs was implemented to ensure reliability of these parameters, primarily QTc.
Pharmacokinetics (PK)
In the single-agent study, samples for CBP501 PK analysis were taken before the infusion start 
DNA Damage Pathway and Repair Biomarker Study
Archival formalin-fixed paraffin-embedded tumor blocks were collected from 10 of the 14 ovarian cancer patients enrolled in the study. These were analyzed immunohistochemically with commercially available antibodies using standard procedures for several markers of DNA repair and DNA damage response pathways, including Rad51, BRCA1, FANCD2, Mus81, polη, XPF, ATM and phospho-MAPKAP-K2. Positive and negative control slides, and a commercial tumor microarray (TMA) containing approximately 75 ovarian cancers, were stained simultaneously.
Stained slides were imaged on the Aperio Scanscope Digital Pathology platform. Tumor regions were annotated by a certified pathologist. Biomarker-specific automated scoring algorithms were employed, in which 50-100 nuclei per tumor field were rated from 0-3 for intensity of staining and samples were assigned a score (designated QIM), calculated as 3 x (% 3+ cells) + 2 x (% 2+ cells) + 1 x (% 1+ cells). A composite score for each sample was obtained by averaging the sum of the QIM scores for the various biomarkers. Individual QIM scores and composite scores were correlated with best response to CBP501/cisplatin treatment.
Statistical methods
These studies were designed to establish the MTD of each regimen: sample size was not based on statistical considerations. Descriptive statistics are used: continuous variables are summarized using N, mean, standard deviation, median, minimum and maximum. Categorical variables are presented using frequencies and percentages. Adverse events, classified according to MedDRA and NCI-CTCAE (Version 3.0), were summarized by incidence and classified by the worst observed grade. Based on the small sample size in the biomarker study, trends correlating immunohistochemical scores and best response were described, but no formal statistical analysis was performed. (Table 2 ); a total of 68 cycles were administered, with a median 2 cycles per patient (range 1-8). The majority of patients (26 patients, 87%) discontinued due to progressive disease; two patients discontinued at investigator discretion, one patient withdrew consent, and one patient died due to an AE (sepsis, unrelated to treatment).
CBP501/Cisplatin. Forty-eight patients were treated in 7 dose levels, with the highest dose level being 36.4 mg/m² CBP501 and 75 mg/m² cisplatin ( Table 2 ). The most frequent tumor types were ovarian cancer and malignant pleural mesothelioma. A total of 182 cycles were administered, with a median 2 cycles per patient (range 1-13). At the recommended dose, 25 mg/m² CBP501 and 75 mg/m² cisplatin, 24 patients were treated, receiving 94 cycles. Fourteen of these patients were enrolled following a protocol amendment to evaluate additional ovarian or endometrial cancer patients. 
Dose-Limiting Toxicity and Definition of Maximum Tolerated Doses
CBP501 single agent. Twenty-seven patients were assessable for determination of MTD. The three non-assessable patients (one in each of DL 0.9, DL 3.6, and DL 22.5) experienced disease progression less than 21 days after treatment initiation. Only one DLT was reported (Table 2) DLTs were reported in 6 evaluable patients; both patients experienced grade 3 histamine-release syndrome (HRS). In both cases, hospitalization was unnecessary and no respiratory or hemodynamic consequences were observed. The severity was determined as grade 3 based on the degree of erythema of the skin rash induced. The MTD was thus defined as the dose level immediately below: 25 mg/m² CBP501 and 75 mg/m² cisplatin. Of note, the occurrence of grade 1-2 HRS determined that CBP501 dose escalations represented only 33% or 50% increases in the highest dose levels in each study. Three patients were discontinued due to treatment-related adverse events: grade 2 ototoxicity (DL I), grade 1 sensory neuropathy and nausea (DL III), grade 3 neutropenia and grade 2 thrombocytopenia (DL VI). Twelve patients (25%) underwent dose reductions. CBP501 alone was reduced in one patient due to fatigue; cisplatin alone was reduced in ten patients, due to persistent nausea (2), severe peripheral neuropathy (2), fatigue (1) and decrease of the glomerular filtration rate (5); both agents were reduced in one patient due to HRS and nausea.
Histamine-mediated adverse events
The principal AE was a histamine-release syndrome (HRS), variably reported as "allergic reaction", "acute infusion reaction", "rash", "urticaria", "erythema", or "pruritus". The reaction was characterized by rash, hot flushes, and urticaria, starting in the head, neck and upper chest 10-60 minutes after initiation of the infusion. The reaction lasted from minutes to a few hours, and was controllable with additional doses of steroids and diphenhydramine. The protocolspecified prophylactic regimen attenuated but did not completely prevent the reaction. Reactions were usually reported after the first dose in cycle 1, and typically recurred in subsequent cycles 
without change in severity. The reaction showed some CBP501 dose-dependency, as the two grade 3 events qualifying as DLTs in the combination study both occurred at the highest dose level explored. No respiratory or hemodynamic changes were reported, and no patients were hospitalized due to HRS. One patient discontinued from the study due to this reaction.
Histamine-mediated adverse events were reported in 18 patients (60%) treated with CBP501 alone, and 34 patients (71%) receiving CBP501 in combination with cisplatin, including two patients (4%) with grade 3 events.
In multiple patients the reaction caused temporary interruption in the treatment administration. A protocol amendment allowed prolongation of the infusion of CBP501 to 2 hours. In the combination study, nine patients (19%) received a prolonged infusion, but the incidence of HRS was not reduced and the duration of the infusion returned to the original 1 hour. 
Cardiac monitoring
CBP501
dose-limiting. This increase was an isolated occurrence, with no creatinine phosphokinase (CPK) elevations and no changes in ECG compared with baseline. This event could have been due to the patient's pericardial infiltration, but was also considered as possibly related to the study drug.
Another patient, treated with single-agent CBP501 at 12.7 mg/m², experienced increased troponin I 30 days after receiving the last dose; ECG and echocardiogram were performed, with no clinically significant findings, and the troponin I increase was not considered clinically relevant.
CBP501/Cisplatin. Centralized ECG review was performed for the 48 patients enrolled. QTcF (Fridericia formula) prolongation to >470 msec was observed in 2 patients, one with hypertension, hypomagnesemia and hypothyroidism and the other with significant cardiac history. Two patients had QTcF prolongation > 60 msec above baseline, one of them also with a prolongation to > 470 msec. None of the patients had a QT interval > 500 msec according to the Fridericia formula, but using Bazett's formula, a QT-interval > 500 msec was observed in one patient during cycle 9. The patient, who received 13 cycles without dose reduction, had a history of coronary artery bypass, aortic and carotid repair, hypertension and peripheral vascular disease, and at cycle 9 presented a transient QTc prolongation to 504 msec; however, the patient completed 13 cycles without clinically relevant cardiac events. No ≥ grade 2 left ventricular ejection fraction (LVEF) decreases considered treatment-related or clinically significant cardiac isoenzyme abnormalities were observed.
Pharmacokinetics
Twenty-nine patients were assessable for pharmacokinetics in the single-agent trial, and 25 in the combination trial. CBP501 half-life was 1.2 to 1.7 hours for doses up to 10 mg/m², increasing to approximately 3.5 hours at 25 mg/m². The tendency for longer CBP501 half-life with increasing doses is attributable to the measurability of later time points at higher dose levels; in the lower dose levels, concentrations at 24 hours were generally less than the lower limit of quantification.
C max and AUC 0-∞ showed dose-proportionality over the dose range evaluated on days 1 and 15 for single-agent administration, as was C max on day 1 in combination with cisplatin ( Fig. 1) . Due to the increase in measured half-life at higher doses, AUC 0-∞ had higher values at 25 and 36.45 mg/m² than would be expected from dose-proportionality at low doses, but did show proportionality over the range from 16.2 to 36.45 mg/m². In both studies, inter-patient variability within dose levels was moderate, with a coefficient of variation generally in the range 20% -40%. In the combination study, CBP501 pharmacokinetics at 25 mg/m 2 were comparable in seven patients when administered alone on day -7 and on day 1 with cisplatin. No consistent differences were observed between CBP501 PK on day 1 and day 15, or between single-agent and combination administration (Table 4) . Cisplatin pharmacokinetic parameters were consistent with single-agent cisplatin administration (Table 4 and Supplementary Fig. S1 ).
Efficacy
CBP501 single agent. Among the 30 patients treated, no objective responses were observed.
Seven patients experienced stable disease (SD) as best response according to RECIST, including 4 patients with SD lasting at least 3 months. Two of these patients were progression free for over 
DNA Damage Response and DNA Repair Biomarker Study
Several markers relevant to repair of cisplatin-induced DNA damage (32) (33) (34) were analyzed immunohistochemically among tumors of 10 ovarian cancer patients treated at the MTD in the combination study. Markers related to homologous recombination repair included Rad51, BRCA1, ATM, FANCD2, MUS81 (35) . XPF and polη were evaluated as markers of nucleotide excision repair and translesion synthesis, respectively (36, 37) . ATM and phospho-MAPKAP-K2, which phosphorylates CDC25C at Ser 216 (11) , were used to assess the DNA damage response. For each of the 8 biomarkers tested, a dynamic range of expression (assessed by QIM score) was detected across the samples tested (test samples and the TMA). Test samples did not cluster within the larger continuum of samples, so the range of expression mirrored that within the TMA population, as shown for Rad51 and phospho-MAPKAP-K2 ( Fig. 2A and B) .
Among the markers for homologous recombination, FANCD2 and MUS81 showed no apparent correlation with response to the cisplatin/CBP501 combination. However, for Rad51, BRCA1
and ATM, patients whose best response was progressive disease (PD) tended to have higher QIM scores than patients who achieved PR or SD. This was particularly true for Rad51, where there was no overlap between QIM scores of patients who derived clinical benefit and those who did not ( Fig. 2A and Supplementary Table S2 ). Similar trends were also observed for the DNA repair pathway biomarkers XPF and Polη (Supplementary Table S2 ). Additionally, expression of phospho-MAPKAP-K2, activity of which may be inhibited by CBP501, also tended to be 
higher in patients with PD ( Fig. 2B and Supplementary Table S2) . Finally, an average of QIM scores for Rad51, BRCA1, ATM, XPF, polη and phospho-MAPKAP K2 yielded composite scores that tended to be higher in patients with PD ( Fig. 2C and Supplementary Table S2) . Taken together, these data suggest that compromised DNA repair and DNA damage response pathways may predict response to the cisplatin/CBP501 combination.
Discussion
Cancer cell-selective G2 checkpoint abrogation following cisplatin by CBP501, a synthetic peptide inhibitor of CDC25C Ser 216 phosphorylation, prompted a development program intended to exploit tumor-intrinsic G1 checkpoint defects and optimize combination therapies. Based on weak activity of CBP501 in several preclinical models (28) , intrinsic DNA damage that can occur in genetically unstable tumor cells, and the need to evaluate CBP501 alone in this first-inhuman experience, we conducted a phase I single-agent trial. In order to translate the synergism of CBP501 and cisplatin, a phase I combination study was also performed.
As predicted by preclinical toxicology (30, 31) , CBP501 was frequently associated with HRS in humans. This was attenuated, but not prevented by diphenhydramine, dexamethasone, ranitidine and loratadine. The allergic reaction dictated the dose escalation process in both studies, appeared dose-dependent, and was not associated with respiratory or hemodynamic problems. It is likely that this non-cytolytic histamine-release activity is related primarily to the presence of the basic arginine amino acid residues in the structure of CBP501 (38, 39).
Assessment of cardiac parameters was performed because the initial repeat-dose toxicology studies reported treatment-related minimum to mild, focal and multifocal myocardial fibrosis in 
the hearts of rats treated at 0.5 mg/kg, associated with non-specific histamine release events (31).
Subsequent cardiovascular safety pharmacology studies confirmed that the effects of CBP501 are attributable to induction of histamine release rather than a direct effect on cardiac tissues (31).
The lack of clinically significant adverse findings after extensive cardiac monitoring suggests that there is minimal risk of cardiotoxicity associated with CBP501 treatment. In summary, aside from HRS, CBP501 was well tolerated, without enhancement of toxicities usually associated with cisplatin.
CBP501/cisplatin showed promising evidence of activity in platinum-resistant or refractory ovarian cancer and mesothelioma. The biomarker study using archival specimens was performed on a small sample of tumors from patients with ovarian cancer. Expression of markers of DNA repair tended to be higher in patients whose best response was PD and lower in patients who achieved PR or SD. Although we cannot rule out the possibility that these markers simply predict outcome to cisplatin alone, the results suggest that the addition of CBP501 is unlikely to overcome intact DNA repair pathways, at least in tumors where expression of DNA repair proteins is robust. In such tumors, repair may occur even if there is G2 checkpoint abrogation.
Of note, the presence of germline BRCA1 or BRCA2 mutation did not correlate with patient outcome in the small group examined. One patient with BRCA1 mutation, who experienced substantial radiographic progression between cycles 2 and 3, had a lower BRCA1 QIM score than other progressors, but a high Rad51 QIM score and a high composite score. Another patient with BRCA1 mutation, whose tumor was not analyzed, progressed after 2 cycles. In these heavily pre-treated patients, BRCA1 reversion mutation following prior cisplatin exposure is a possibility (40) . A third patient with a BRCA1 alteration of unknown significance achieved partial response, and another patient with BRCA2 mutation had stable disease; both of these patients had low Rad 51 QIM scores (Supplementary Table S2 ).
Interestingly, high levels of phospho-MAPKAP-K2 expression were also found in patients with PD. Since CBP501 is expected to inhibit the ability of this kinase to phosphorylate CDC25C at 
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